The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Peptide Antibiotics-Global Market Insights and Sales Trends 2025
Synopsis
The global Peptide Antibiotics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Peptide Antibiotics in various end use industries. The expanding demands from the Pharma & Healthcare, Food Industry, Commodities and Other, are propelling Peptide Antibiotics market. Ribosomal Synthesized Peptide Antibiotics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Ribosomally Synthesized Peptide Antibiotics segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Peptide Antibiotics market, driven by demand from China, the second largest economy with some signs of stabilising, the Peptide Antibiotics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peptide Antibiotics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peptide Antibiotics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peptide Antibiotics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peptide Antibiotics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peptide Antibiotics covered in this report include Pfizer, Novartis, GlaxoSmithKline, Eli Lilly, Theravance, Vicuron Pharmaceuticals, Savara Pharmaceuticals, AMP Therapeutics and Hospira, etc.
The global Peptide Antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
GlaxoSmithKline
Eli Lilly
Theravance
Vicuron Pharmaceuticals
Savara Pharmaceuticals
AMP Therapeutics
Hospira
Kasten
Madam Therapeutics
Phosphagenics
Pacgen Life Science Corporation
Global Peptide Antibiotics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peptide Antibiotics market, Segment by Type:
Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomally Synthesized Peptide Antibiotics
Global Peptide Antibiotics market, by Application
Pharma & Healthcare
Food Industry
Commodities
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Peptide Antibiotics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Peptide Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Peptide Antibiotics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Peptide Antibiotics in various end use industries. The expanding demands from the Pharma & Healthcare, Food Industry, Commodities and Other, are propelling Peptide Antibiotics market. Ribosomal Synthesized Peptide Antibiotics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Ribosomally Synthesized Peptide Antibiotics segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Peptide Antibiotics market, driven by demand from China, the second largest economy with some signs of stabilising, the Peptide Antibiotics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peptide Antibiotics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peptide Antibiotics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peptide Antibiotics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peptide Antibiotics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peptide Antibiotics covered in this report include Pfizer, Novartis, GlaxoSmithKline, Eli Lilly, Theravance, Vicuron Pharmaceuticals, Savara Pharmaceuticals, AMP Therapeutics and Hospira, etc.
The global Peptide Antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
GlaxoSmithKline
Eli Lilly
Theravance
Vicuron Pharmaceuticals
Savara Pharmaceuticals
AMP Therapeutics
Hospira
Kasten
Madam Therapeutics
Phosphagenics
Pacgen Life Science Corporation
Global Peptide Antibiotics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peptide Antibiotics market, Segment by Type:
Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomally Synthesized Peptide Antibiotics
Global Peptide Antibiotics market, by Application
Pharma & Healthcare
Food Industry
Commodities
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Peptide Antibiotics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Peptide Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Peptide Antibiotics Market Overview
1.1 Peptide Antibiotics Product Overview
1.2 Peptide Antibiotics Market Segment by Type
1.2.1 Ribosomal Synthesized Peptide Antibiotics
1.2.2 Non-Ribosomally Synthesized Peptide Antibiotics
1.3 Global Peptide Antibiotics Market Size by Type
1.3.1 Global Peptide Antibiotics Market Size Overview by Type (2018-2029)
1.3.2 Global Peptide Antibiotics Historic Market Size Review by Type (2018-2023)
1.3.3 Global Peptide Antibiotics Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Peptide Antibiotics Sales Breakdown by Type (2018-2023)
1.4.2 Europe Peptide Antibiotics Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Peptide Antibiotics Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Peptide Antibiotics Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Peptide Antibiotics Sales Breakdown by Type (2018-2023)
2 Global Peptide Antibiotics Market Competition by Company
2.1 Global Top Players by Peptide Antibiotics Sales (2018-2023)
2.2 Global Top Players by Peptide Antibiotics Revenue (2018-2023)
2.3 Global Top Players by Peptide Antibiotics Price (2018-2023)
2.4 Global Top Manufacturers Peptide Antibiotics Manufacturing Base Distribution, Sales Area, Product Type
2.5 Peptide Antibiotics Market Competitive Situation and Trends
2.5.1 Peptide Antibiotics Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Peptide Antibiotics Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Antibiotics as of 2022)
2.7 Date of Key Manufacturers Enter into Peptide Antibiotics Market
2.8 Key Manufacturers Peptide Antibiotics Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Peptide Antibiotics Status and Outlook by Region
3.1 Global Peptide Antibiotics Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Peptide Antibiotics Historic Market Size by Region
3.2.1 Global Peptide Antibiotics Sales in Volume by Region (2018-2023)
3.2.2 Global Peptide Antibiotics Sales in Value by Region (2018-2023)
3.2.3 Global Peptide Antibiotics Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Peptide Antibiotics Forecasted Market Size by Region
3.3.1 Global Peptide Antibiotics Sales in Volume by Region (2024-2029)
3.3.2 Global Peptide Antibiotics Sales in Value by Region (2024-2029)
3.3.3 Global Peptide Antibiotics Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Peptide Antibiotics by Application
4.1 Peptide Antibiotics Market Segment by Application
4.1.1 Pharma & Healthcare
4.1.2 Food Industry
4.1.3 Commodities
4.1.4 Other
4.2 Global Peptide Antibiotics Market Size by Application
4.2.1 Global Peptide Antibiotics Market Size Overview by Application (2018-2029)
4.2.2 Global Peptide Antibiotics Historic Market Size Review by Application (2018-2023)
4.2.3 Global Peptide Antibiotics Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Peptide Antibiotics Sales Breakdown by Application (2018-2023)
4.3.2 Europe Peptide Antibiotics Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Peptide Antibiotics Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Peptide Antibiotics Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Peptide Antibiotics Sales Breakdown by Application (2018-2023)
5 North America Peptide Antibiotics by Country
5.1 North America Peptide Antibiotics Historic Market Size by Country
5.1.1 North America Peptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Peptide Antibiotics Sales in Volume by Country (2018-2023)
5.1.3 North America Peptide Antibiotics Sales in Value by Country (2018-2023)
5.2 North America Peptide Antibiotics Forecasted Market Size by Country
5.2.1 North America Peptide Antibiotics Sales in Volume by Country (2024-2029)
5.2.2 North America Peptide Antibiotics Sales in Value by Country (2024-2029)
6 Europe Peptide Antibiotics by Country
6.1 Europe Peptide Antibiotics Historic Market Size by Country
6.1.1 Europe Peptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Peptide Antibiotics Sales in Volume by Country (2018-2023)
6.1.3 Europe Peptide Antibiotics Sales in Value by Country (2018-2023)
6.2 Europe Peptide Antibiotics Forecasted Market Size by Country
6.2.1 Europe Peptide Antibiotics Sales in Volume by Country (2024-2029)
6.2.2 Europe Peptide Antibiotics Sales in Value by Country (2024-2029)
7 Asia-Pacific Peptide Antibiotics by Region
7.1 Asia-Pacific Peptide Antibiotics Historic Market Size by Region
7.1.1 Asia-Pacific Peptide Antibiotics Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Peptide Antibiotics Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Peptide Antibiotics Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Peptide Antibiotics Forecasted Market Size by Region
7.2.1 Asia-Pacific Peptide Antibiotics Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Peptide Antibiotics Sales in Value by Region (2024-2029)
8 Latin America Peptide Antibiotics by Country
8.1 Latin America Peptide Antibiotics Historic Market Size by Country
8.1.1 Latin America Peptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Peptide Antibiotics Sales in Volume by Country (2018-2023)
8.1.3 Latin America Peptide Antibiotics Sales in Value by Country (2018-2023)
8.2 Latin America Peptide Antibiotics Forecasted Market Size by Country
8.2.1 Latin America Peptide Antibiotics Sales in Volume by Country (2024-2029)
8.2.2 Latin America Peptide Antibiotics Sales in Value by Country (2024-2029)
9 Middle East and Africa Peptide Antibiotics by Country
9.1 Middle East and Africa Peptide Antibiotics Historic Market Size by Country
9.1.1 Middle East and Africa Peptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Peptide Antibiotics Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Peptide Antibiotics Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Peptide Antibiotics Forecasted Market Size by Country
9.2.1 Middle East and Africa Peptide Antibiotics Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Peptide Antibiotics Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer Peptide Antibiotics Products Offered
10.1.5 Pfizer Recent Development
10.2 Novartis
10.2.1 Novartis Company Information
10.2.2 Novartis Introduction and Business Overview
10.2.3 Novartis Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Novartis Peptide Antibiotics Products Offered
10.2.5 Novartis Recent Development
10.3 GlaxoSmithKline
10.3.1 GlaxoSmithKline Company Information
10.3.2 GlaxoSmithKline Introduction and Business Overview
10.3.3 GlaxoSmithKline Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.3.4 GlaxoSmithKline Peptide Antibiotics Products Offered
10.3.5 GlaxoSmithKline Recent Development
10.4 Eli Lilly
10.4.1 Eli Lilly Company Information
10.4.2 Eli Lilly Introduction and Business Overview
10.4.3 Eli Lilly Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Eli Lilly Peptide Antibiotics Products Offered
10.4.5 Eli Lilly Recent Development
10.5 Theravance
10.5.1 Theravance Company Information
10.5.2 Theravance Introduction and Business Overview
10.5.3 Theravance Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Theravance Peptide Antibiotics Products Offered
10.5.5 Theravance Recent Development
10.6 Vicuron Pharmaceuticals
10.6.1 Vicuron Pharmaceuticals Company Information
10.6.2 Vicuron Pharmaceuticals Introduction and Business Overview
10.6.3 Vicuron Pharmaceuticals Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Vicuron Pharmaceuticals Peptide Antibiotics Products Offered
10.6.5 Vicuron Pharmaceuticals Recent Development
10.7 Savara Pharmaceuticals
10.7.1 Savara Pharmaceuticals Company Information
10.7.2 Savara Pharmaceuticals Introduction and Business Overview
10.7.3 Savara Pharmaceuticals Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Savara Pharmaceuticals Peptide Antibiotics Products Offered
10.7.5 Savara Pharmaceuticals Recent Development
10.8 AMP Therapeutics
10.8.1 AMP Therapeutics Company Information
10.8.2 AMP Therapeutics Introduction and Business Overview
10.8.3 AMP Therapeutics Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.8.4 AMP Therapeutics Peptide Antibiotics Products Offered
10.8.5 AMP Therapeutics Recent Development
10.9 Hospira
10.9.1 Hospira Company Information
10.9.2 Hospira Introduction and Business Overview
10.9.3 Hospira Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Hospira Peptide Antibiotics Products Offered
10.9.5 Hospira Recent Development
10.10 Kasten
10.10.1 Kasten Company Information
10.10.2 Kasten Introduction and Business Overview
10.10.3 Kasten Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Kasten Peptide Antibiotics Products Offered
10.10.5 Kasten Recent Development
10.11 Madam Therapeutics
10.11.1 Madam Therapeutics Company Information
10.11.2 Madam Therapeutics Introduction and Business Overview
10.11.3 Madam Therapeutics Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Madam Therapeutics Peptide Antibiotics Products Offered
10.11.5 Madam Therapeutics Recent Development
10.12 Phosphagenics
10.12.1 Phosphagenics Company Information
10.12.2 Phosphagenics Introduction and Business Overview
10.12.3 Phosphagenics Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Phosphagenics Peptide Antibiotics Products Offered
10.12.5 Phosphagenics Recent Development
10.13 Pacgen Life Science Corporation
10.13.1 Pacgen Life Science Corporation Company Information
10.13.2 Pacgen Life Science Corporation Introduction and Business Overview
10.13.3 Pacgen Life Science Corporation Peptide Antibiotics Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Pacgen Life Science Corporation Peptide Antibiotics Products Offered
10.13.5 Pacgen Life Science Corporation Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Peptide Antibiotics Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Peptide Antibiotics Industrial Chain Analysis
11.4 Peptide Antibiotics Market Dynamics
11.4.1 Peptide Antibiotics Industry Trends
11.4.2 Peptide Antibiotics Market Drivers
11.4.3 Peptide Antibiotics Market Challenges
11.4.4 Peptide Antibiotics Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Peptide Antibiotics Distributors
12.3 Peptide Antibiotics Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
